Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PIQUR Therapeutics

Request full access

Clinical-stage oncology drugs targeting PI3K/mTOR pathways

Basel, SwitzerlandFounded 2011Biotech & Life Sciences

About PIQUR Therapeutics

PIQUR Therapeutics AG was a Swiss clinical-stage pharmaceutical company focused on developing anti-cancer drugs by inhibiting the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) signaling pathways. The company was established in August 2011 as a spin-off from the University of Basel.

The company was co-founded by Dr. Vladimir Cmiljanovic and his sister, Dr. Natasa Cmiljanovic. Their work on what would become the company's lead drug candidate originated during their Ph.D. studies at the University of Basel. Dr. Vladimir Cmiljanovic, a medicinal chemist and serial entrepreneur, led the company as CEO, securing significant funding and winning accolades such as the Swiss Economic Forum Award in 2015.

PIQUR's primary asset was bimiralisib (also known as PQR309), an oral, brain-penetrant, dual PI3K/mTOR inhibitor. This compound was developed for targeted cancer therapy and showed potential in treating various tumors, including those affecting the brain, due to its ability to cross the blood-brain barrier. The company advanced PQR309 through multiple Phase 1 and Phase 2 clinical trials for advanced solid tumors, lymphomas, and in combination with other drugs for breast cancer. The business model centered on the discovery and clinical development of these proprietary drug candidates, aiming for partnerships and licensing agreements with larger pharmaceutical firms. For instance, PIQUR entered into a collaboration with Pierre Fabre for dermato-oncology.

Over its operational period, PIQUR raised more than CHF 100 million in funding from private investors and venture capital firms like Versant Ventures. Despite its promising research and clinical progress, the company was officially liquidated in 2022. In 2023, Swiss Rockets AG, an incubator co-founded by the Cmiljanovics in 2018, acquired all assets and intellectual property of Piqur. These assets were subsequently transferred to a new entity, Torqur AG, which continues the development of bimiralisib and a pipeline of next-generation PI3K/mTOR inhibitors.

Source: Dealroom company data

PIQUR Therapeutics in the Basel ecosystem

Live from Dealroom

The PIQUR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Team profiled 18 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PIQUR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PIQUR Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.